Research Article
A Cell Cycle Progression-Derived Gene Signature to Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma
Figure 4
The CCP-derived gene signature is a robust prognostic predictor of HCC. (a) Distribution of CCP-derived RS across HCC patients in the LIRI-JP cohort. The high- and low-risk groups were separated in line with the median of RS (dotted line). (b) Distribution of survival status in high- and low-risk groups in the LIRI-JP cohort. (c) Heat map visualizing the mRNA expression of six candidate variables in high- and low-risk groups the LIRI-JP cohort. Yellow, upregulation and blue, downregulation. (d) Prognostic analyses of HCC patients with high and low RS in the LIRI-JP cohort. (e, f) Uni- and multivariate cox regression models of CCP-derived RS and clinicopathological parameters in TCGA-LIHC cohort. (g) ROC curves at 1-, 3-, and 5-year survival in TCGA-LIHC cohort. (h) ROC curves at 1-, 3-, and 5-year survival in the LIRI-JP cohort.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |
(h) |